Prediction of urinary symptoms after 125iodine prostate brachytherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72574
Title:
Prediction of urinary symptoms after 125iodine prostate brachytherapy.
Authors:
Kelly, Karen L; Swindell, Ric; Routledge, Jacqueline A; Burns, Meriel P; Logue, John P; Wylie, James P
Abstract:
AIMS: To evaluate the post-treatment urinary morbidity experienced by a cohort of men undergoing ultrasound-based transperineal prostate brachytherapy, as monotherapy for early stage carcinoma of the prostate. MATERIALS AND METHODS: One hundred and thirty-four consecutive patients received prostate brachytherapy between March 2000 and July 2002, and were asked to complete the International Prostate Symptom Score (IPSS) and Hospital Anxiety and Depression (HAD) questionnaires before treatment and at 1, 3, 6, 9, 12 and 18 months after implant. Data on catheterisation and surgical interventions were also recorded. Pre-treatment IPSS, dosimetry and other variables were analysed in relation to catheterisation rates and post-treatment IPSS scores at each time window. RESULTS: One hundred and eleven patients returned sufficient data for meaningful analysis. Of the patients who completed IPSS at 1 month, 85 (97%) reported deterioration in IPSS scores. This peak of symptoms, identified by a rise in median IPSS, started to improve by 3 months, and was approaching baseline by 18 months. The only significant determinants of early urinary toxicity were pre-treatment IPSS, pre-treatment prostate volume and the difficulty of implant. However, prostate volume was not significant beyond 1 month. Twenty-six patients required catheterisation at a median of 10 days after implant. Significant predictors of urinary retention were pre-treatment prostate volume and pre-treatment IPSS. Patients requiring catheterisation continued to have significantly higher IPSS at 18 months than patients who had never required a catheter. CONCLUSION: Brachytherapy was generally well tolerated, with urinary toxicity in most patients persisting for at least 3-6 months after prostate brachytherapy. Those whose pre-treatment prostate volume and IPSS were high experienced more severe urinary symptoms in the first few months.
Affiliation:
Department of Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK.
Citation:
Prediction of urinary symptoms after 125iodine prostate brachytherapy. 2006, 18 (4):326-32 Clin Oncol
Journal:
Clinical Oncology
Issue Date:
May-2006
URI:
http://hdl.handle.net/10541/72574
PubMed ID:
16703751
Type:
Article
Language:
en
ISSN:
0936-6555
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorKelly, Karen L-
dc.contributor.authorSwindell, Ric-
dc.contributor.authorRoutledge, Jacqueline A-
dc.contributor.authorBurns, Meriel P-
dc.contributor.authorLogue, John P-
dc.contributor.authorWylie, James P-
dc.date.accessioned2009-07-06T11:12:22Z-
dc.date.available2009-07-06T11:12:22Z-
dc.date.issued2006-05-
dc.identifier.citationPrediction of urinary symptoms after 125iodine prostate brachytherapy. 2006, 18 (4):326-32 Clin Oncolen
dc.identifier.issn0936-6555-
dc.identifier.pmid16703751-
dc.identifier.urihttp://hdl.handle.net/10541/72574-
dc.description.abstractAIMS: To evaluate the post-treatment urinary morbidity experienced by a cohort of men undergoing ultrasound-based transperineal prostate brachytherapy, as monotherapy for early stage carcinoma of the prostate. MATERIALS AND METHODS: One hundred and thirty-four consecutive patients received prostate brachytherapy between March 2000 and July 2002, and were asked to complete the International Prostate Symptom Score (IPSS) and Hospital Anxiety and Depression (HAD) questionnaires before treatment and at 1, 3, 6, 9, 12 and 18 months after implant. Data on catheterisation and surgical interventions were also recorded. Pre-treatment IPSS, dosimetry and other variables were analysed in relation to catheterisation rates and post-treatment IPSS scores at each time window. RESULTS: One hundred and eleven patients returned sufficient data for meaningful analysis. Of the patients who completed IPSS at 1 month, 85 (97%) reported deterioration in IPSS scores. This peak of symptoms, identified by a rise in median IPSS, started to improve by 3 months, and was approaching baseline by 18 months. The only significant determinants of early urinary toxicity were pre-treatment IPSS, pre-treatment prostate volume and the difficulty of implant. However, prostate volume was not significant beyond 1 month. Twenty-six patients required catheterisation at a median of 10 days after implant. Significant predictors of urinary retention were pre-treatment prostate volume and pre-treatment IPSS. Patients requiring catheterisation continued to have significantly higher IPSS at 18 months than patients who had never required a catheter. CONCLUSION: Brachytherapy was generally well tolerated, with urinary toxicity in most patients persisting for at least 3-6 months after prostate brachytherapy. Those whose pre-treatment prostate volume and IPSS were high experienced more severe urinary symptoms in the first few months.en
dc.language.isoenen
dc.subject.meshAged-
dc.subject.meshBrachytherapy-
dc.subject.meshHumans-
dc.subject.meshIodine Radioisotopes-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshProspective Studies-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshQuestionnaires-
dc.subject.meshRisk Assessment-
dc.subject.meshRisk Factors-
dc.subject.meshTreatment Outcome-
dc.subject.meshUrinary Catheterization-
dc.subject.meshUrination Disorders-
dc.titlePrediction of urinary symptoms after 125iodine prostate brachytherapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalClinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.